TNF-α induced secretion of HMGB1 from non-immune canine mammary epithelial cells (MTH53A)

Cytokine

Volumn 57, Issue 2, 2012, Pages 210-220

  Willenbrock, Saskia ^a,b   Braun, Olga ^b   Baumgart, Judith ^c   Lange, Sandra ^d   Junghanss, Christian ^d   Heisterkamp, Alexander ^e   Nolte, Ingo ^a   Bullerdiek, Jörn ^a,b   Murua Escobar, Hugo ^a  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c LASER ZENTRUM HANNOVER E V   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Canis familiaris; Cytokines; HMGB1; Secretion; Tumor

Indexed keywords

GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CELL LINE; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLUORESCENCE ANALYSIS; GENETIC TRANSFECTION; MEMBRANE STRUCTURE; MULTIPHOTON MICROSCOPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; TIME; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL EXTRACTS; CELL LINE; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; GREEN FLUORESCENT PROTEINS; HMGB1 PROTEIN; HUMANS; INTERFERON-GAMMA; LASERS; MAMMARY GLANDS, ANIMAL; MICROSCOPY, FLUORESCENCE; NECROSIS; REPRODUCIBILITY OF RESULTS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANIS FAMILIARIS;

EID: 84855463690     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.11.011     Document Type: Article

References (59)

1. MacEwen E.G., Patnaik A.K., Harvey H.J., Panko W.B. Estrogen receptors in canine mammary tumors. Cancer Res 1982, 42:2255-2259.
2. Khanna C., Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005, 26:513-523.
3. Withrow S.J., MacEwen E.G. Clinical veterinary oncology 1989, Lippincott Williams & Wilkins, Philadelphia (USA).
4. MacEwen E.G. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990, 9:125-136.
5. Nolte I., Nolte M. Praxis der onkologie bei hund und katze 2000, Enke Verlag, Stuttgart.
6. Withrow S.J., MacEwen E.G. Small animal clinical oncology 2001, W.B. Saunders Co., Philadelphia, USA.
7. Murua Escobar H., Meyer B., Richter A., Becker K., Flohr A.M., Bullerdiek J., et al. Molecular characterization of the canine HMGB1. Cytogenet Genome Res 2003, 101:33-38.
8. Brezniceanu M.L., Volp K., Bosser S., Solbach C., Lichter P., Joos S., et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003, 17:1295-1297.
9. Flohr A.M., Rogalla P., Meiboom M., Borrmann L., Krohn M., Thode-Halle B., et al. Variation of HMGB1 expression in breast cancer. Anticancer Res 2001, 21:3881-3885.
10. Walker J.M., Goodwin G.H., Johns E.W., Wietzes P., Gaastra W. A comparison of the amino-terminal sequences of two calf-thymus chromatin non-histone proteins. Int J Pept Protein Res 1977, 9:220-223.
11. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001, 26:152-153.
12. Wolffe A.P. Architectural transcription factors. Science 1994, 264:1100-1101.
13. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999, 19:5237-5246.
14. Onate S.A., Prendergast P., Wagner J.P., Nissen M., Reeves R., Pettijohn D.E., et al. The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol Cell Biol 1994, 14:3376-3391.
15. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
16. Andersson U., Tracey K.J. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 2004, 30:627-637. xi.
17. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.
18. Wang H., Vishnubhakat J.M., Bloom O., Zhang M., Ombrellino M., Sama A., et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999, 126:389-392.
19. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
20. Semino C., Angelini G., Poggi A., Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005, 106:609-616.
21. Kawahara K., Biswas K.K., Unoshima M., Ito T., Kikuchi K., Morimoto Y., et al. C-reactive protein induces high-mobility group box-1 protein release through activation of p38MAPK in macrophage RAW264.7 cells. Cardiovasc Pathol 2008, 17:129-138.
22. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
23. Abraham E., Arcaroli J., Carmody A., Wang H., Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000, 165:2950-2954.
24. Rendon-Mitchell B., Ochani M., Li J., Han J., Wang H., Yang H., et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003, 170:3890-3897.
25. Ulloa L., Batliwalla F.M., Andersson U., Gregersen P.K., Tracey K.J. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 2003, 48:876-881.
26. Yang H., Ochani M., Li J., Qiang X., Tanovic M., Harris H.E., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004, 101:296-301.
27. Wahamaa H., Vallerskog T., Qin S., Lunderius C., LaRosa G., Andersson U., et al. HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay. J Leukoc Biol 2007, 81:129-136.
28. Kuniyasu H., Yano S., Sasaki T., Sasahira T., Sone S., Ohmori H. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages. Am J Pathol 2005, 166:751-760.
29. Liu S., Stolz D.B., Sappington P.L., Macias C.A., Killeen M.E., Tenhunen J.J., et al. HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix-induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol 2006, 290:C990-C999.
30. Fujii K., Luo Y., Sasahira T., Denda A., Ohmori H., Kuniyasu H. Co-treatment with deoxycholic acid and azoxymethane accelerates secretion of HMGB1 in IEC6 intestinal epithelial cells. Cell Prolif 2009, 42:701-709.
31. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995, 270:25752-25761.
32. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
33. Yu M., Wang H., Ding A., Golenbock D.T., Latz E., Czura C.J., et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006, 26:174-179.
34. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
35. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
36. Huttunen H.J., Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 2004, 255:351-366.
37. Helmlinger G., Netti P.A., Lichtenbeld H.C., Melder R.J., Jain R.K. Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 1997, 15:778-783.
38. Zhang C.L., Shu M.G., Qi H.W., Li L.W. Inhibition of tumor angiogenesis by HMGB1 A box peptide. Med Hypotheses 2008, 70:343-345.
39. Schlueter C., Weber H., Meyer B., Rogalla P., Roser K., Hauke S., et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005, 166:1259-1263.
40. Tlsty T.D., Coussens L.M. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006, 1:119-150.
41. Laster S.M., Wood J.G., Gooding L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988, 141:2629-2634.
42. Mitola S., Belleri M., Urbinati C., Coltrini D., Sparatore B., Pedrazzi M., et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol 2006, 176:12-15.
43. Dumitriu I.E., Baruah P., Manfredi A.A., Bianchi M.E., Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 2005, 26:381-387.
44. Yang H., Wang H., Tracey K.J. HMG-1 rediscovered as a cytokine. Shock 2001, 15:247-253.
45. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
46. Ulloa L., Ochani M., Yang H., Tanovic M., Halperin D., Yang R., et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002, 99:12351-12356.
47. Zamora R., Grishin A., Wong C., Boyle P., Wang J., Hackam D., et al. High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol 2005, 289:G643-G652.
48. Ulloa L., Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 2006, 17:189-201.
49. Li J., Wang H., Mason J.M., Levine J., Yu M., Ulloa L., et al. Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods 2004, 289:211-223.
50. Ossowski L., Biegel D., Reich E. Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell 1979, 16:929-940.
51. Parkkinen J., Rauvala H. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J Biol Chem 1991, 266:16730-16735.
52. Campana L., Bosurgi L., Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008, 20:518-523.
53. van Beijnum J.R., Buurman W.A., Griffioen A.W. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 2008, 11:91-99.
54. Sagoo P., Chan G., Larkin D.F., George A.J. Inflammatory cytokines induce apoptosis of corneal endothelium through nitric oxide. Invest Ophthalmol Vis Sci 2004, 45:3964-3973.
55. Suk K., Kim S., Kim Y.H., Kim K.A., Chang I., Yagita H., et al. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol 2001, 166:4481-4489.
56. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002, 3:995-1001.
57. Sharma M., Beck A.H., Webster J.A., Espinosa I., Montgomery K., Varma S., et al. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat 2009.
58. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr Opin Genet Dev 2005, 15:97-101.
59. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.